Avacta Group provides innovative products and expert services to solve high value problems for the drug development and diagnosticssectors through two market facing companies, Avacta Analytical and AvactaAnimal Health.
Avacta’s core competence lies in making the power of advanced analyticaltechnology accessible through a range of solution-focused products andservices.
Avacta’s primary aim is to equip biopharmaceuticaldevelopers and manufacturers with tools to get their products to market quickerand with reduced cost – reducing risk in the drug development process andoptimising product performance. Avacta’s first technology product, Optim,and the Company’s expert services make this possible by permitting compounds tobe analysed in much greater detail at an earlier stage in the drug developmentcycle than can currently be achieved, thereby providing timely identificationof problems that can cause costly late stage failures or poor productperformance.
Avacta’s core technology is being further developed to provide diagnostictesting at the point of care with an initial focus on the veterinary healthcaremarket. The company provides diagnostic testing services relating to allergy tomore than 50% of UK vets andhas distributors in the EU and Far East.Avacta’s first point-of-care technology, Midas, which is a rapid blood testsystem will launch into the veterinary market in 2010 and will then be appliedto human diagnostics challenges.
Avacta has grown organically, and through four acquisitions,from a small Universityof Leeds spin-out in 2005into a dynamic technology development and contract services company with fiftyemployees in the two market-facing operating businesses and the cross-groupR&D and laboratory services teams.